Psoriasiform Spongiotic Dermatitis Drug Eruption following Pfizer-BioNTech SARS-CoV-2 mRNA Vaccine Administration
Main Article Content
Keywords
COVID-19, Drug Eruption, Psoriasiform Spongiotic Dermatitis, morbilliform rash
Abstract
Introduction: Cutaneous manifestations such as morbilliform rashes, lichen planus, and local injection site patches have been recently published in case reports to occur within days of receiving the coronavirus disease 2019 (COVID-19) vaccine. The most common drug eruptions have been noted to be delayed hypersensitivity reactions.
Objective: To spotlight a vaccine drug eruption case in a patient with a long history of the autoimmune condition, psoriasis vulgaris.
Case Presentation: A 51-year-old Caucasian female presented with pruritic and erythematous rashes covering her back, abdomen, pelvis, and both upper extremities emerging one week after receiving the Pfizer BioNTech mRNA vaccine. The rashes worsened, rapidly spreading toward the lower extremities within five days after her second dose. The patient was diagnosed with psoriasiform spongiotic dermatitis compatible with a drug eruption and began loratadine and clobetasol cream treatment and phototherapy.
Conclusion: With limited published data available on skin reactions to the COVID-19 vaccine, our case report is among one of the first presentations to describe a morbilliform rash induced by a Pfizer BioNTech mRNA drug-eruption. Although this is a rare case, we may expect more reported drug eruptions to be documented as mass vaccinations continue to be dispensed across the globe. Physicians must be prepared to accurately diagnose and treat dermatologic conditions on patients with and without pre-existing illnesses.
References
2. Rice, S. M., Ferree, S. D., Mesinkovska, N. A. & Kourosh, A. S. The art of prevention: COVID-19 vaccine preparedness for the dermatologist. Int. J. Women’s Dermatology 7, 209–212 (2021).
3. Mintoff, D., Pisani, D., Betts, A. & Scerri, L. SARS-CoV-2 mRNA Vaccine-Associated Fixed Drug Eruption. J. Eur. Acad. Dermatol. Venereol. 1–3 (2021) doi:10.1111/jdv.17390.
4. Jedlowski, P. M. & Jedlowski, M. F. Morbilliform rash after administration of pfizer-biontech covid-19 mrna vaccine. Dermatol. Online J. 27, 0–3 (2021).
5. Corbeddu, M. et al. Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series. J. Eur. Acad. Dermatology Venereol. (2021) doi:10.1111/jdv.17268.
6. Hiltun, I. et al. Lichen planus arising after COVID-19 vaccination. J. Eur. Acad. Dermatology Venereol. 5–6 (2021) doi:10.1111/jdv.17221.
7. Soyfer, V., Gutfield, O., Shamai, S., Schlocker, A. & Merimski, O. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-. Int. J. Radiat. Oncol. 1–5 (2021).
8. Fattori, A. et al. Cutaneous manifestations in patients with coronavirus disease 2019: clinical and histological finding. Hum. Pathol. 107, 39–45 (2020).
9. Singh, S. et al. Assessment of histopathological features of maculopapular viral exanthem and drug-induced exanthem. J. Cutan. Pathol. 44, 1038–1048 (2017).
10. Mcmahon, D. E. et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination : A registry-based study of 414 cases. J. Am. Acad. Dermatology 85, 46–55 (2021).
11. Kulkarni, R. B., Lederman, Y., Afiari, A., Savage, J. A. & Jacob, J. Morbilliform Rash: An Uncommon Herald of SARS-CoV-2. Cureus 12, 10–15 (2020).
12. Ziegler, C. G. K. et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell 181, 1016-1035.e19 (2020).
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.